Modality
Bispecific Ab
MOA
AHRant
Target
IL-13
Pathway
Autophagy
WM
Development Pipeline
Preclinical
Nov 2018
→ Jun 2030
PreclinicalCurrent
NCT04841703
245 pts·WM
2018-11→2030-06·Recruiting
NCT05678279
2,423 pts·WM
2024-06→TBD·Terminated
2,668 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-244.2y awayInterim· WM
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Recruit…
Preclinical
Termina…
Catalysts
Interim
2030-06-24 · 4.2y away
WM
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04841703 | Preclinical | WM | Recruiting | 245 | PANSS |
| NCT05678279 | Preclinical | WM | Terminated | 2423 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 |